Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2

Sharad K. Verma(GlaxoSmithKline (United States)), William H. Miller(Clinical Innovations (United States)), Alan P. Graves(GlaxoSmithKline (United States)), Michael T. McCabe(GlaxoSmithKline (United States)), Art Shu(GlaxoSmithKline (United States)), Louis V. LaFrance(Johnson & Johnson (United States)), Steven D. Knight(GlaxoSmithKline (United States)), Xinrong Tian(GlaxoSmithKline (United Kingdom)), James Brackley(GlaxoSmithKline (United States)), Stuart P. Romeril(GlaxoSmithKline (United States)), Céline Duquenne(GlaxoSmithKline (United Kingdom)), Peter J. Tummino(Intarcia Therapeutics (United States)), Elsie Diaz(Johnson & Johnson (United States)), Heidi M. Ott(GlaxoSmithKline (United Kingdom)), D. Scherzer(GlaxoSmithKline (United States)), Glenn S. Van Aller(GlaxoSmithKline (United Kingdom)), Ryan G. Kruger(Arysta LifeScience (France)), Neil W. Johnson(Brandywine Photonics (United States)), Joelle L. Burgess(GlaxoSmithKline (United States)), Caretha L. Creasy, Seth W. Grant(GlaxoSmithKline (United States)), Yong Jiang(GlaxoSmithKline (United States)), Carl A. Machutta(South College), Kenneth A. Newlander(GlaxoSmithKline (United States)), Dominic Suarez(GlaxoSmithKline (United States)), Christine Thompson(GlaxoSmithKline (United Kingdom)), Dashyant Dhanak(Wilmington University)
ACS Medicinal Chemistry Letters
October 19, 2012
Cited by 377


Related Papers